Background & Summary
====================

CONVERGE^[@b1]^ is the largest whole-genome sequencing cohort representative of the Han Chinese population to date. It is also the most comprehensive collection of sequence variants from any non-Caucasian population.

The 1000 Genomes Project^[@b2]^, Hapmap project^[@b5]^, the Human Genome Diversity Project^[@b6]^ (HGDP) and most recently assembly of many population based cohorts in the Haplotype Reference Consortium have enabled the study of genetic diversity in human populations and the building of population reference panels for checking any new cohorts against as well as genotype imputation. Despite these efforts, most genetic studies have mostly been conducted in European and African populations. Examples of relatively large GWAS on East Asian populations on schizophrenia^[@b7]^, IgA nephrology^[@b8]^, prostate cancer^[@b9]^ and systemic lupus erythematosus^[@b10]^ have discovery sample sizes below 2,000 cases. In comparison, more diseases are studied using the GWAS method on populations of European descent, more cohorts were collected by independent groups for each disease, many of them are aggregated in large consortiums for joint analysis, and as such have sample sizes at least a scale of magnitude larger. Some examples include the Wellcome Trust Case Control Consortium Phase 1 ([@b11]) (WTCCC-1, all samples of European descent), the DIAGRAM Consortium for type-II diabetes^[@b12]^ (34,840 cases and 114,981 controls, mostly of European descent), the CardioGRAM Consortium^[@b13]^ for coronary artery disease (60,801 cases and 123,504 controls, mostly of European descent), the CHARGE Consortium^[@b14]^ (38,000 samples, all analyses restricted to Europeans or European Americans) and most recently, the UKBiobank and 23andMe datasets each containing hundreds of thousands of samples and numerous quantitative and qualitative traits reflective of human physiology and lifestyle.

Few methods^[@b15]^ had been developed to analyze cross population data, and significant success has only recently been achieved in meta-analysis^[@b16]^. Such successes have also been limited to genetic loci that have similar allele frequency distributions in different populations. Most resources such as recombination maps, linkage disequilibrium (LD) maps, and particular disease related gene annotations^[@b17]^ being developed with and drawing information mostly from European populations, and population specific ones are increasing in numbers but still exceptions^[@b20]^ rather than the norm. CONVERGE samples^[@b1]^ consist of cases of recurrent MD collected from 58 provincial mental health centres and psychiatric departments of general medical hospitals in 45 cities and 23 provinces of China. A similar number of controls are recruited from patients undergoing minor surgical procedures at general hospitals (37%) or from local community centres (63%). While these data are collected for the investigation of genetics of severe recurrent MDD in the Han Chinese population, sequence data from this dataset are a resource for population genetics studies on the Han Chinese population. In particular, these data can be used as a reference panel for future design of genotyping arrays specific to the Han Chinese population, and as comparison with other populations in the investigation of human evolution and migration. LD maps, recombination maps and allele frequency spectrums can be generated from this dataset for use as reference for Han Chinese or other related East Asian populations.

In addition, the presence of mitochondrial sequence data at an average coverage of 102X in all CONVERGE samples^[@b21],[@b22]^ can be used to trace the maternal lineage of the Han Chinese population. We have previously reported mitochondrial DNA copy number is under genetic control^[@b22]^; there are potentially other molecular traits detectable from whole-genome sequencing data under genetic control.

CONVERGE is the largest genetic resource derived from next generation whole genome sequencing (WGS) and it showcases the utility of low-coverage WGS in providing high quality genotypes for GWAS at common variant sites. We outline the tested practices in sequence data processing, variant calling, variant filtering, imputation and downstream quality control, setting a benchmark for future studies using low coverage WGS for GWAS and other genetic analyses.

Methods
=======

Sample collection
-----------------

CONVERGE collected cases of recurrent MDD from 58 provincial mental health centres and psychiatric departments of general medical hospitals in 45 cities and 23 provinces of China. Controls were recruited from patients undergoing minor surgical procedures at general hospitals (37%) or from local community centres (63%). Cases were excluded if they had a pre-existing history of bipolar disorder, psychosis or mental retardation. Cases were aged between 30 and 60 and had two or more episodes of MDD meeting DSM-IV criteria^[@b23]^ with the first episode occurring between 14 and 50 years of age, and had not abused drugs or alcohol before their first depressive episode. All subjects were interviewed using a computerized assessment system. Interviewers were postgraduate medical students, junior psychiatrists or senior nurses who had gone through at least a week of training by the CONVERGE team. The diagnosis of MDD was established with the Composite International Diagnostic Interview (CIDI) (WHO lifetime version 2.1; Chinese version), which utilized DSM-IV criteria. The interview was translated into Mandarin by a team of psychiatrists in Shanghai Mental Health Centre, with the translation reviewed and modified by members of the CONVERGE team.

DNA sequencing
--------------

DNA was extracted from saliva samples using the Oragene protocol. A barcoded library was constructed for each sample. Sequencing reads obtained from Illumina Hiseq machines were aligned to Genome Reference Consortium Human Build 37 patch release 5 (GRCh37.p5) with Stampy (v1.0.17)^[@b24]^ using default parameters, after filtering out reads containing adaptor sequencing or consisting of more than 50% poor quality (base quality\<=5) bases. Samtools (v0.1.18)^[@b25]^ was used to index the alignments in BAM format^[@b25]^ and Picardtools (v1.62) was used to mark PCR duplicates for downstream filtering. The Genome Analysis Toolkit's (GATK, version 2.6)^[@b26]^ Base quality score recalibration (BQSR) was then applied to the mapped sequencing reads using BaseRecalibrator in Genome Analysis Toolkit (GATK, basic version 2.6)^[@b26]^ with the known insertion and deletion (INDEL) variations in 1000 Genomes Projects Phase 1 and known single nucleotide polymorphisms (SNPs) from dbSNP (v137, excluding all sites added after v129) excluded from the empirical error rate calculation. GATKlite (v2.2.15)^[@b26]^ was then used to output sequencing reads with the recalibrated base quality scores while removing reads without the 'proper pair' flag bit set by Stampy (1--5% of reads per sample) using the \--read_filter ProperPair option (if the 'proper pair' flag bit is set for a pair of reads, it means both reads in the mate-pair are correctly oriented, and their separation is within 5 standard deviations from the mean insert size between mate-pairs).

Calling and imputation of genotypes at SNPs included in GWAS
------------------------------------------------------------

Variant discovery and genotyping (for both SNPs and INDELs) at all polymorphic SNPs in 1000G Phase1 East Asian (ASN) reference panel^[@b3]^ was performed simultaneously using post-BQSR sequencing reads from all samples using the GATK's UnifiedGenotyper (version 2.7-2-g6bda569) using option \--genotype_likelihood_model BOTH and default annotation outputs for variant calls. dbSNP v137 rsids were used to fill in the variant ID column of the result variant call format (VCF) files using the \--dbSNP option. Variant quality score recalibration (VQSR) was then performed with GATK's VariantRecalibrator (v2.7-4-g6f46d11) in SNP variant calls using the SNPs in 1000 Genomes Phase 1 ASN Panel^[@b3]^ as the known, truth and training sets with a prior of 15.0, and the following default annotations: -an QD -an HaplotypeScore -an MQRankSum -an ReadPosRankSum -an FS -an MQonly. A sensitivity threshold of 90% to SNPs in the 1000G Phase1 ASN panel was applied for SNP selection for imputation after optimizing for Transition to Transversion (TiTv) ratios in SNPs called. Genotype likelihoods (GLs) were calculated at selected sites using a sample-specific binomial mixture model implemented in SNPtools (version 1.0)^[@b27]^, and imputation was performed at those sites without a reference panel using BEAGLE (version 3.3.2)^[@b28]^. A second round of imputation was performed with BEAGLE on the same GLs, but only at biallelic SNPs polymorphic in the 1000G Phase 1 ASN panel using the 1000G Phase 1 ASN haplotypes as a reference panel. A final set of allele dosages and genotype probabilities was generated from these two datasets by replacing the results in the former with those in the latter at all sites imputed in the latter. We then applied a conservative set of inclusion threshold for SNPs for genome-wide association study (GWAS): (a) *P*-value for violation HWE \> 10^−6^, (b) Information score \> 0.9, (c) MAF in CONVERGE \> 0.5% to arrive at the final set of 6,242,619 SNPs for individual genotype analsyses.

Haplotype calling
-----------------

The genotypes derived from Beagle imputation were phased using Shapeit (version 2, revision 790)^[@b29]^. Genetic maps were obtained from the Impute2 ([@b30]) website. Chromosomes 13--22 and X were phased using 12 threads and default parameters. Chromosomes 1--12 were phased using 12 threads in four chunks that overlap by 1MB. The phased chunks were ligated together using ligateHAPLOTYPES, available from the Shapeit website.

Ethical approval
----------------

The study protocol was approved centrally by the Ethical Review Board of Oxford University (Oxford Tropical Research Ethics Committee) and the ethics committees of all participating hospitals in China. All interviewers were mental health professionals who are well able to judge decisional capacity. The study posed minimal risk (an interview and saliva sample). All participants provided their written informed consent.

Data Records
============

Sequence data
-------------

Sequencing data of 11,670 samples in paired FASTQ files are available from the European Nucleotide Archive (ENA) at Study and Short Read Archive Accession PRJNA289433 (Data Citation 1). Data totals about 100 terabytes (TB); after download, alignment of raw sequence data in paired FASTQ format to Genome Reference Consortium Human Build 37 patch release 5 (GRCh37.p5) with BWA takes not more than 2 h per FASTQ file (4 h per pair) and less than 5 gigabytes (GB) of RAM per process. Once in BAM format, preprocessing steps can be parallelized per sample using less than 12GB of RAM and 2 h on a single processor.

SNP variant calls from sequence data
------------------------------------

A list of high quality SNP variant sites^[@b1]^ with major and minor alleles and allele frequencies in both the CONVERGE cohort and 1000 Genomes Phase 1 ASN samples in variant call format (VCF) is provided through Figshare (Data Citation 2).

Imputation and genotypes
------------------------

We imputed genotype probabilities and obtained alternative allele dosages at 22,847,544 SNPs from all autosomes and chromosome X including 20,539,441 SNPs in the CONVERGE cohort and all polymorphic sites in the 1000 Genomes ASN Panel on all 11,670 CONVERGE samples, as detailed in Cai *et al.*^[@b1]^ (Data Citation 2). After applying stringent quality controls, we obtained 10,640 samples (5,303 cases of MDD, 5,337 controls) for inclusion in GWAS of MDD^[@b1]^. We have submitted all imputed genotypes at 20,539,441 SNPs of these 10,640 samples passing quality control in VCF format to the European Variations Archive (EVA), Accession PRJNA289433 (same Accession as the sequence data, see 'Analysis Files' on ENA study page, Data Citation 3); access will be brokered through the EVA with standard application procedures. SNPs with imputation information score below 0.95 (a higher threshold than we had used for our GWAS analysis) are marked 'INFO0.95' instead of 'PASS'. Minor allele frequency, *P* value for violation of Hardy-Weinberg equilibrium and imputation information score are also present in the INFO column of the VCFs. As CONVERGE is part of Phase 2 of the Haplotype Reference Consortium^[@b31]^ (HRC), these data will also be available in the near future through the HRC.

Genome wide association study summary statistics
------------------------------------------------

GWAS on MDD and mitochondrial DNA copy number quantified from sequencing data are published^[@b1],[@b22]^; summary statistics for GWAS on MDD is available from the Psychiatric Genomics Consortium (<https://www.med.unc.edu/pgc/files/resultfiles/converge.MDD.summary_stats.2Sep2015.tbl.gz>) and on Figshare (Data Citation 4) and that of mitochondrial DNA copy number for all common SNPs (\>5% MAF) is available on Figshare (Data Citation 5). All phenotypes are currently under analysis, interested research groups and individuals are welcome to contact us directly for collaborations and access.

Technical Validation
====================

These methods are expanded versions of descriptions in our related work Cai *et al.*^[@b1]^.

Whole genome NGS on 11,670 samples
----------------------------------

The coverage of sequencing is the number of times, on average, a single site in the genome is covered by sequencing reads. For each sample in CONVERGE, the average sequencing coverage over the nuclear genome is 1.7x, and that on the mitochondrial genome is 102x ([Fig. 1](#f1){ref-type="fig"}).

Variant calling and variant quality recalibration
-------------------------------------------------

Sets or 'tranches' of SNPs with increasing VQSLOD scores (increasing stringency in exclusion of outliers and concomitant decreasing sensitivity to known SNPs) from VQSR (Methods) were generated at the specified sensitivities to known SNPs using the --tranche option: -tranche 100.0 -tranche 99.9 -tranche 99.0 -tranche 98.0 -tranche 95.0 -tranche 90.0 -tranche 89.0 -tranche 87.0 -tranche 85.0 -tranche 80.0 -tranche 79.0. Transition-to-transversion (TiTv) ratios were calculated for each tranche. [Table 1](#t1){ref-type="table"} summarizes this information. A sensitivity to known SNPs of 90.0% was chosen for the inclusion of novel SNPs in downstream analyses, as it balances optimization of TiTv ratio in novel SNPs with retaining as many potential novel SNPs as possible so as not to lose variant information.

This gave a total of 21,356,798 (9,053,391 known in 1000 Genomes Phase 1 ASN Panel and 11,486,024 novel), biallelic SNPs identified from all chromosomes and unassembled contigs. 20,539,441 SNPs from the autosomes and chromosome X were put forth for imputation of genotype probabilities and downstream analyses. All known sites in 1000 Genomes Phase 1 ASN panel were included in all further analyses regardless of whether they were identified as polymorphic in CONVERGE, and their VQSLOD scores if they were identified as polymorphic in CONVERGE. Numbers of SNPs imputed in each chromosome and the percentage of SNPs in each category are shown in [Table 2](#t2){ref-type="table"}.

Imputation quality
------------------

### Using high coverage (10x) sequencing

Nine samples in CONVERGE were sequenced to an average of 10x coverage using the same Illumina Hiseq platform used for the low-coverage sequencing samples. Mapping and processing of the 10x sequencing reads were performed in an identical fashion as the low-coverage sequences. Variant calling (for both SNPs and INDELs) was performed on the high coverage dataset using sequencing reads from all nine samples with UnifiedGenotyper in GATK (v2.7-2-g6bda569) using option \--genotype_likelihood_model BOTH and default annotation outputs for variant calls. dbSNP v137 rsids are used to fill in the variant ID column of the result variant call format (VCF) files using the \--dbSNP option.

Variant quality score recalibration (VQSR) was performed using two different training sets. The first VQSR was performed using SNP variant calls using the SNPs in 1000 Genomes Phase 1 ASN Panel as the known, truth and training sets with a prior of 15.0 and the default annotations just like it was done for the raw variant calls from the low coverage data, but with two maximum Gaussians for building the positive model instead of one, with the \--maxGaussian option. The second VQSR was performed using SNPs from the HumanOmniZhongHua-8 (v1.0) BeadChip. Sets or 'tranches' of SNPs with increasing VQSLOD scores (increasing stringency in exclusion of outliers and concomitant decreasing sensitivity to known SNPs) were generated at the specified sensitivities to known SNPs using the --tranche option: -tranche 100.0 -tranche 99.9 -tranche 99.0 -tranche 98.0 -tranche 95.0 -tranche 90.0 -tranche 89.0 -tranche 87.0 -tranche 85.0 -tranche 80.0 -tranche 79.0. Transition to Transversion (TiTv) Ratio was calculated for each tranche. A sensitivity to known SNPs in the Zhonghua chip of 90.0% was chosen for the inclusion of novel SNPs in downstream analyses as it balances optimization of TiTv ratio in novel SNPs while retaining as many potential novel SNPs as possible to not lose variant information. This gave a total of 5,914,716 (5,272,185 known in 1000 Genomes Phase 1 ASN Panel and 642,525 novel) biallelic SNPs identified in high coverage sequencing data with which we are able to check for squared Pearson correlation coefficient (r^2^) and concordance with imputed allele dosages and hard-called genotypes of the same samples respectively.

We calculated the percentage concordance between hard-called genotypes from imputed genotype probabilities (where the genotype with the maximum imputed genotype probability\>0.9 was called) and genotypes called from the 10x coverage sequencing data at all imputed variant sites for each of the nine samples. The mean concordance per sample across all sites was 98.1% (s.e.=0.12%) and the percentage concordance calculated for each alternative allele frequencies was shown in [Fig. 2](#f2){ref-type="fig"}.

We also calculated r^2^ between imputed allele dosages and genotypes from the 10x coverage sequencing data at all imputed variant sites for each of the nine samples. The mean r^2^ per sample across all sites was 0.938 (s.e.=0.003). The r^2^ calculated for each alternative allele frequencies is shown in [Fig. 3](#f3){ref-type="fig"}.

[Supplementary Table 1](#S1){ref-type="supplementary-material"} from Cai *et al.*^[@b1]^ combines all these information and shows the mean percentage concordance and Pearson r^2^ among 9 samples for each genotype class (homozygous reference, heterozygous and homozygous alternative) for each alternative allele frequency bin.

### Using HumanOmniZhongHua-8 (v1.0) BeadChip on 72 samples

72 samples from CONVERGE were genotyped on the Illumina HumanOmniZhongHua-8 (v1.0B) BeadChip which contains 898,122 SNPs, optimized for the Chinese population using tag SNPs from all three HapMap phases and the 1000 Genomes Project. Sample genotypes with GenCall score of 0.15 or lower were considered no-calls.

857,766 out of the 895,623 SNPs on the array were included in our imputation (95.77%). Upon examining, why 37,857 SNPs on the array were not imputed, we found that SNPs that were on the array, but not imputed, were not polymorphic in either CONVERGE samples or 1000 Genomes Phase 1 ASN panel. None of the 72 samples genotyped were polymorphic at these 37,857 sites. [Table 3](#t3){ref-type="table"} shows the number of SNPs genotyped on the Zhonghua array on each chromosome, and the call rate among the 72 samples on each chromosome. 855,132 SNPs that showed biallelic polymorphism in CONVERGE or the 1000 Genomes Phase1 ASN Panel and passed genotyping quality filters were used for comparison with imputation results. We calculated the percentage concordance ([Fig. 4](#f4){ref-type="fig"}) and Pearson r^2^ ([Fig. 5](#f5){ref-type="fig"}) between hard-called genotypes and allele dosages from imputation with genotype calls from the ZhongHua8 genotyping array for all 855,132 SNPs on 72 samples. The overall percentage concordance for all 855,132 imputed SNPs genotyped on the array was 98.0% (s.e.=0.04%) and the overall r^2^ was 0.974 (s.e.=0.0005).

[Supplementary Table 2](#S1){ref-type="supplementary-material"} from Cai *et al.*^[@b1]^ shows the mean percentage concordance and Pearson R^2^ among 72 samples for each genotype class (homozygous reference, heterozygous and homozygous alternative) for each alternative allele frequency bin. At all alternative allele frequency bins between 1 to 99%, the mean percentage concordances were above 96% and the mean R^2^s were above 0.87.

### Using Sequenom at 21 sites

11,669 samples out of all CONVERGE samples were genotyped at 21 random sites in the genome using a custom Sequenom SpectroCHIP (1 sample was not genotyped as there was not enough DNA of adequate quality for genotyping on the Sequenom platform). Mass spectra were collected using the MassARRAY system mass spectrometer and TYPER4.0 was used to assess the reliability of genotype calls generated by SpectroREAD from the mass spectra. Default genotype call inclusion criteria were used.

Just as we had compared imputed results with genotypes called directly from 10x coverage sequencing and the Illumina HumanOmniZhongHua Beadchip, we calculated the percentage concordance and r^2^ between hard-called genotypes and allele dosages from imputation with genotype calls from the Sequenom for each of the 21 sites that were genotyped. An r^2^ of 0.988 and concordance of 98.19% were obtained for the 21 sites. Per site r^2^ (mean=0.985) and percentage concordance (mean=98.16%) are shown [Table 4](#t4){ref-type="table"} (also [Supplementary Table 3](#S1){ref-type="supplementary-material"} of Cai *et al.*^[@b1]^) along with the alleles and MAF of each site.

Selection of samples for genetic analyses
-----------------------------------------

### Sample contamination

We performed a range of quality control filters on all 11,670 samples and selected only those samples with high-quality sequencing results and imputed genotype probabilities for downstream analysis.

We first looked into both the nuclear genome and mitochondrial genome for an excess of variants called, since this would indicate cross-sample contamination due to technical issues during sequencing. We quantified the number of singleton variants called in the genic regions of the nuclear genome (Methods) and found a mean of 71.55 singletons variants in exon regions across the whole genome supported by more than 2 sequencing reads passing sequencing quality controls per sample. While most samples fall in a normal distribution with mean of 71.55 singletons, others had excess singletons, which could be indicative of poor DNA quality that compromised sequencing and mapping qualities. We excluded 117 samples with a number of singletons greater than the 99th percentile (237.62 singletons).

We then asked if there were any samples with an excess of heteroplasmic mutations in the mitochondrial DNA per sample. As the DNA for all individuals recruited in CONVERGE were extracted from saliva samples, which would also contain the oral microbiome, external DNA contamination levels could be told from number of mismatches in mapped reads at regions of the genomes where the human genome was similar to bacterial genomes. The mitochondrial DNA in human genome, a 16 kb circular DNA, is one of such instances. Mitochondrial DNA is inherited only from the mother and there is a strict bottleneck in the female germline for mitochondrial DNA, usually only one clonal copy of mitochondrial DNA is inherited at a time. Heteroplasmic variations in the mitochondrial genome (where two or more alleles are present at a single position in the mitochondrial genome of a single individual) are rare and usually occurring at low levels. Mismatches that occur in some sequencing reads mapping to the mitochondrial DNA region of the human genome reference in one sample would therefore indicate either a rare event heteroplasmy, or a contamination from similar DNA sequences of bacterial origins. Samples with excessive numbers of heteroplasmic sites can therefore be suspected as having a higher than normal level of bacterial contamination, and the conservative approach would be to filter them out to ensure the quality of sequencing, and all downstream analyses.

Coverage of the mitochondrial genome is on average 102X, making it possible to obtain high quality sequence for this part of the genome. We called a mean of 15.70 heteroplasmic sites per sample, and 116 samples were found to have greater than the 99th percentile of number of heteroplasmic sites. Of these 116 samples, 26 were already discarded for having excess nuclear genome singletons; we excluded the additional 90 from further analysis.

### Sample relatedness

Varying levels of relatedness could cause inflated *P*-values and even false positive results in GWAS, as alleles inherited together due to high relatedness but not related to etiology of disease could appear so in association testing. To exclude duplicates and first degree relatives from our sample for GWAS, we calculated the proportion IBD (PIHAT, estimated as P(IBD=2)+0.5\*P(IBD=1)) for every pair of samples in CONVERGE using LD pruned SNPs (LD\<0.5). We excluded all pairs of samples (392 samples in total) whose PIHAT exceeded 0.5 and P(IBD=1) exceeded 0.75 from further analyses.

Finally, we also excluded 29 samples with fewer than 90% of imputed sites with maximum genotype probabilities\>0.9, and 402 samples with incomplete phenotype information. We used the remaining set of 10,640 samples (5,303 cases of MDD, 5,337 controls) for GWAS on MDD and mitochondrial DNA levels (Data Citation 4 and Data Citation 5).

Usage Notes
===========

CONVERGE is the largest well-curated, high quality low-coverage WGS dataset from a single study and a single population where all samples are from the same ethnic group. Although sequencing was performed at low coverage, we have shown good quality genotypes can be obtained through recalibration of sequencing base qualities, filtering of variants based on sensitivity to known variants, imputation using a two-step approach, and finally strict quality control over imputed genotypes. We have also shown robust ways of identifying and removing potentially contaminated samples using sequencing data, particularly where the source of DNA was saliva. We have ensured there are no related individuals in this dataset for downstream genetic analysis, and we recommend using genotypes of SNPs with high imputation information scores, available in the VCF we provide through EVA (Data Citation 3) in future analyses. We encourage all users of CONVERGE data to use and expand upon on these quality control measures especially when performing analyses on rare, copy number and structural variants, for which we do not currently have gold standards in low coverage WGS. Development of methods and best practices for these purposes can enable more economical sequencing of large cohorts, and the usage of existing data to the fullest.

The CONVERGE project has the aim of studying MDD in a homogenous population where genetic ancestry and cultural diversity minimally confound genetic effects. Hospital staff, trained to use computer-assisted interviews, obtained highly detailed information on clinical symptoms, comorbidities, personality traits, social support, socio-economic status, life style, and major stressful life events. All cases of MDD collected in CONVERGE had severe and recurrent MDD not concurrent with other major illnesses (85% of cases of MDD in CONVERGE come under the severe subtype with somatic symptoms, Melancholia). The use of screened controls limited the possibility of including undiagnosed cases of MDD in the study. These, together with strict inclusion criteria for ancestry, age (between 30 to 60) and sex (only females) of all samples in CONVERGE, made CONVERGE the most homogenous and extensively phenotyped cohort of severe, recurrent MDD and matched controls to date.

MDD is a highly heterogeneous disease with different ages of onset and physiological symptoms, prevalence between sexes, definitions across cultural contexts and diagnostic instruments. In addition to heterogeneity in the disease presentation, misdiagnoses and biases in self-reporting further contribute to heterogeneity in studies with less detailed enquiry, documentation and classification of MDD phenotypes. Until recently, GWAS has not been able to uncover genetic loci associated with MDD due to the complex genetic architecture^[@b32]^ (commonly thought to consist of small effects from numerous common genetic variants) compounded with heterogeneity in disease identification and characteristics. The estimated number of samples needed for uncovering a genetic locus associated with this heterogenous disease was 50,000 cases and a similar number of controls. In CONVERGE we have shown that using stringent criteria and deep phenotyping to minimise misdiagnosis and biases in self-reporting, we were able to find and replicate two genetic associations to MDD using a tenth of the estimated sample size. Thus, in some cases, dissection of disease etiology through studying clearly defined and rigorously collected phenotypes can lead to a substantial increase in power to detect genetic effects. We note the contrast in strategy with a recent study using data from 23andMe that reported 15 genetic associations with 30 times our sample size and a yet bigger departure from our definition of MDD^[@b33]^. It will take further investigations to know if and how these new genetic associations from a large but heterogenous cohort may contribute to genetic heterogeneity in MDD.
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![Sequencing coverage per sample in CONVERGE.\
This figure shows the mean sequencing coverage per site in the nuclear and mitochondrial genome per sample for 11,670 samples in CONVERGE; the mean sequencing coverage over the nuclear genome is 1.7X and that over the mitochondrial genome is 102X.](sdata201711-f1){#f1}

![Percentage concordance between hard-called genotypes from imputed genotype probabilities and genotypes called from 10x coverage sequencing in nine samples.\
This figure shows the percentage concordance between genotypes from imputation (hard-called as the genotype with the maximum imputed genotype probability, barring those where the maximum genotypes probability was smaller than 0.9 in which case the genotypes was considered missing) and genotypes directly called from 10x coverage sequencing data in nine samples. Each box contains data points for nine samples; the vertical axis shows the percentage of SNPs per sample in each alternative allele frequency bracket (horizontal axis) with concordant genotypes between the two datasets.](sdata201711-f2){#f2}

![Aggregate Pearson r^2^ between imputed allele dosages and genotypes called from 10x coverage sequencing in nine samples.\
This figure shows the aggregate Pearson r^2^ between imputed alternative allele dosages with genotypes called directly from 10x coverage sequencing data in nine samples. Each box contains data points for nine samples; the vertical axis shows aggregate Pearson r^2^ of all SNPs in each alternative allele frequency bracket (horizontal axis) with concordant genotypes between that imputed alternative allele dosages and directly called from 10x coverage sequencing data.](sdata201711-f3){#f3}

![Percentage concordance between hard-called genotypes from imputed genotype probabilities and genotypes from the Illumina HumanOmniZhongHua Beadchip in 72 samples.\
This figure shows the percentage concordance between genotypes from imputation (hard-called as the genotype with the maximum imputed genotype probability, barring those where the maximum genotypes probability was smaller than 0.9 in which case the genotypes was considered missing) and genotypes directly called from Illumina HumanOmniZhongHua Beadchip in 72 samples. Each box contains data points for nine samples; the vertical axis shows the percentage of SNPs per sample in each alternative allele frequency bracket (horizontal axis) with concordant genotypes between the two datasets.](sdata201711-f4){#f4}

![Aggregate Pearson r^2^ between imputed allele dosages and genotypes called from Illumina HumanOmniZhongHua Beadchip in 72 samples.\
This figure shows the aggregate Pearson r^2^ between imputed alternative allele dosages with genotypes called directly from 10x coverage sequencing data in nine samples. Each box contains data points for nine samples; the vertical axis shows aggregate Pearson r^2^ of all SNPs in each alternative allele frequency bracket (horizontal axis) with concordant genotypes between that imputed alternative allele dosages and directly called from Illumina HumanOmniZhongHua Beadchip in 72 samples.](sdata201711-f5){#f5}

###### Transition-Transversion (TiTv) ratio for known and novel SNPs discovered in CONVERGE in different tranches of sensitivities to known SNPs in 1000 Genomes Phase 1 ASN Panel.

  **Sensitivity to Known SNPs (%)**    **Number of SNPs**              **TiTv Ratio**  
  ----------------------------------- -------------------- ---------- ---------------- --------
  79                                        7946865         9361731        2.1783       2.1998
  80                                        8047459         9502607        2.1786       2.2011
  85                                        8550425         10357018       2.1817       2.204
  87                                        8751611         10853838       2.1838       2.2042
  89                                        8952798         11310561       2.1862       2.1961
  90                                        9053391         11486024       2.187        2.1868
  95                                        9556357         13089943       2.1849       1.9637
  98                                        9858137         15716679       2.1759       1.6553
  99                                        9958730         17362038       2.1721       1.5296
  99.9                                      10049264        20940831       2.1683       1.353
  100                                       10059324        22722016       2.168        1.2839

###### Imputed SNPs in CONVERGE.

  **Chr**    **All Imputed**   **Known in 1000 Genomes Phase 1 ASN Panel**                     **Novel in CONVERGE**                               **Used in GWAS**            
  --------- ----------------- --------------------------------------------- --------- ------- ----------------------- -------- ------- ---------- ------------------ --------- -------
  chr1           1906566                         1049943                     709178    67.54          340765           32.456   55.07    856623         44.93         473126    24.82
  chr2           2080626                         1141277                     768281    67.32          372996           32.682   54.85    939349         45.15         504269    24.24
  chr3           1730976                         971680                      660330    67.96          311350           32.042   56.14    759296         43.87         444601    25.69
  chr4           1683635                         963695                      655100    67.98          308595           32.022   57.24    719940         42.76         452165    26.86
  chr5           1552865                         866733                      586899    67.71          279834           32.286   55.82    686132         44.19         395356    25.46
  chr6           1542585                         895135                      602872    67.35          292263           32.65    58.03    647450         41.97         416919    27.03
  chr7           1386630                         780333                      519815    66.62          260518           33.385   56.28    606297         43.72         357113    25.75
  chr8           1352488                         743135                      500602    67.36          242533           32.636   54.95    609353         45.05         330591    24.44
  chr9           1049711                         587643                      394219    67.09          193424           32.915   55.98    462068         44.02         264762    25.22
  chr10          1204931                         669919                      456560    68.15          213359           31.848   55.6     535012          44.4         310998    25.81
  chr11          1203686                         662829                      443108    66.85          219721           33.149   55.07    540857         44.93         297679    24.73
  chr12          1141658                         644071                      435882    67.68          208189           32.324   56.42    497587         43.59         294448    25.79
  chr13          858815                          486316                      334096    68.7           152220           31.301   56.63    372499         43.37         225668    26.28
  chr14          793487                          445316                      303662    68.19          141654           31.81    56.12    348171         43.88         201734    25.42
  chr15          722748                          397917                      266748    67.04          131169           32.964   55.06    324831         44.94         175810    24.33
  chr16          793223                          418892                      276272    65.95          142620           34.047   52.81    374331         47.19         178608    22.52
  chr17          674848                          363982                      238795    65.61          125187           34.394   53.94    310866         46.07         150405    22.29
  chr18          683315                          386244                      265213    68.67          121031           31.335   56.53    297071         43.48         173158    25.34
  chr19          542027                          299517                      192281    64.2           107236           35.803   55.26    242510         44.74         128700    23.74
  chr20          552234                          294881                      200864    68.12           94017           31.883   53.4     257353          46.6         127726    23.13
  chr21          324063                          182937                      123793    67.67           59144           32.33    56.45    141126         43.55          83062    25.63
  chr22          334001                          180274                      119161    66.1            61113            33.9    53.98    153727         46.03          79845    23.91
  chrX           943020                          404837                      265078    65.48          139759           34.522   42.93    538183         57.07         175876    18.65
  Total         25058138                        13837506                     9318809   67.35          4518697          32.655   55.22   11220632        44.78         6242619   24.91

###### **SNPs genotyped per chromosome on Illumina HumanOmniZhongHua Beadchip.**

  **Chromosome**    **All Array SNPs**   **No Calls**   **Not Polymorphic**   **Used For Comparison**
  ---------------- -------------------- -------------- --------------------- -------------------------
  chr1                    69485               5                3199                    66126
  chr2                    70071               3                2958                    66928
  chr3                    60192               7                2608                    57516
  chr4                    53419               1                2478                    50807
  chr5                    52477               1                2142                    50307
  chr6                    62652               15               2555                    59930
  chr7                    47158               4                1909                    45157
  chr8                    45906               0                1824                    44062
  chr9                    40597               0                1521                    38996
  chr10                   46134               1                1971                    44131
  chr11                   42894               1                1971                    40888
  chr12                   42849               3                1822                    40950
  chr13                   32399               1                1451                    30931
  chr14                   28777               1                1167                    27594
  chr15                   27769               3                1099                    26647
  chr16                   29448               3                1276                    28146
  chr17                   25411               1                1145                    24252
  chr18                   27117               1                1104                    26003
  chr19                   18919               4                 956                    17942
  chr20                   21918               2                 843                    21057
  chr21                   12613               1                 500                    12103
  chr22                   14056               1                 480                    13538
  chrX                    23362               1                 869                    21121
  chrY                     2041              1208               833                      0
  chrM                     151                0                 151                      0
  chrXY                    307               307                 0                       0
  Total                   898122             1575              38832                  855132

###### **Validation of imputation results with genotypes at 21 sites on custom Sequenom SpectroCHIP on all samples.**

       **SNP**        **RSID**    **REF**   **ALT**   **FREQ**   **N Samples**   **Con (%)**   **Pearson r**^**2**^
  ----------------- ------------ --------- --------- ---------- --------------- ------------- ----------------------
    chr1:11205058    rs1057079       C         T        0.8          11645          99.85             0.998
    chr1:47398743    rs3890011       G         C       0.525         11625          99.95             0.999
   chr2:141751592    rs13007735      G         A       0.595         11652          99.8              0.998
   chr2:204824283    rs10172036      T         G       0.434         9561           94.69             0.957
    chr2:99779131    rs2516835       T         C       0.651         11533          99.58             0.997
   chr3:186443018    rs1656922       T         C       0.356         11634          99.64             0.996
    chr7:47968927    rs2686817       C         A       0.522         11621          99.09             0.992
   chr8:143310815    rs11167136      G         A       0.498         11618          98.61             0.987
   chr9:125424507     rs70156        A         C        0.5          11632          94.8              0.962
   chr10:120917445   rs2275111       G         A       0.707         11651          99.54             0.995
   chr10:95279506    rs2293277       A         T       0.565         11506          95.62             0.966
   chr12:120995332   rs2292681       G         A       0.767         11653          99.88             0.998
   chr13:31233063    rs3742302       G         A       0.153         11651          99.91             0.998
   chr14:20665840    rs4981088       G         A       0.507         11508          93.92             0.954
   chr15:77344793     rs11737        T         A       0.415         11628          99.69             0.997
   chr15:90226947    rs7169981       C         A       0.317         11615          98.92              0.99
   chr16:20986506    rs3115438       C         T       0.481         11423          99.79             0.998
    chr17:5991344    rs2302836       C         T       0.829         11652          96.52             0.955
   chr18:61170721    rs1455556       T         C       0.546         11631          97.73             0.983
   chr20:50238545    rs2235862       A         G       0.237         11649          99.8              0.997
   chr20:52786219    rs2296241       G         A       0.417         11638          93.99              0.96

[^1]: J.F. and K.S.K. designed the project; J.F. and K.S.K. obtained funding for the project; Y.L., J.F., and K.S.K. collected the samples; N.C., W.W.K., J.L., J.H., Q.L., R.M., J.F. performed the genome sequencing and analysis of data quality; W.W.K., J.H., L.S., Q.L., N.C., J.M. performed the genotype imputation; N.C., T.B.B., Y.L., W.W.K., R.E.P., S.B., T.B.W., B.R., K.S.K., J.M., R.M. and J.F. performed the genetic analysis; N.C. and J.F. prepared the manuscript. All authors have read and approved the final manuscript.
